KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Total Non-Current Liabilities data on record, last reported at $317.7 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 27.29% year-over-year to $317.7 million; the TTM value through Dec 2025 reached $317.7 million, down 27.29%, while the annual FY2025 figure was $317.7 million, 27.29% down from the prior year.
  • Total Non-Current Liabilities reached $317.7 million in Q4 2025 per ACAD's latest filing, down from $399.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $436.9 million in Q4 2024 and bottomed at $145.9 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $270.9 million, with a median of $266.7 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 69.38% in 2023, then decreased 27.29% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $152.2 million in 2021, then grew by 17.17% to $178.3 million in 2022, then skyrocketed by 69.38% to $302.1 million in 2023, then soared by 44.65% to $436.9 million in 2024, then fell by 27.29% to $317.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $317.7 million in Q4 2025, $399.6 million in Q3 2025, and $374.6 million in Q2 2025.